Defying FDA: Shanghai Lab Gets Warning Letter But Won’t Relent
A Shanghai testing laboratory has been handed an FDA warning letter for refusing a GMP inspection but has shot back at the US agency, saying it rightfully did so.
You may also be interested in...
The latest big pharma vote of confidence in both the China market and R&D capabilities comes amid continuing standoffs with the US over a flurry of issues including the coronavirus, national security and trade, but as the pandemic seemingly recedes in China.
From AI-assisted drug discovery to oncotherapy development, China has seen investment pour in over the past week, while the nation's largest online pharmacy is readying for a big Hong Kong debut.
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.